Seagen
Seagen is a global biotechnology company that develops and commercializes innovative antibody-based therapies for the treatment of cancer. The company is known for its industry-leading antibody-drug conjugate (ADC) technology platform, which harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.
History[edit | edit source]
Seagen was founded in 1998 under the name Seattle Genetics. The company changed its name to Seagen in 2020 to reflect its growth and global presence. Since its inception, Seagen has been at the forefront of cancer research, developing a diverse portfolio of therapies and a robust pipeline of investigational drugs.
Antibody-Drug Conjugate (ADC) Technology[edit | edit source]
Seagen's Antibody-Drug Conjugate (ADC) technology is a targeted cancer therapy that delivers cytotoxic chemotherapy ("payload") to cancer cells via an antibody that specifically binds to a particular protein expressed on the cells. This approach is designed to spare non-targeted cells, thus reducing many of the toxic effects of traditional chemotherapy while enhancing antitumor activity.
Products[edit | edit source]
Seagen's product portfolio includes ADCETRIS (brentuximab vedotin), PADCEV (enfortumab vedotin-ejfv), and TUKYSA (tucatinib). These products have been approved by the U.S. Food and Drug Administration (FDA) and are used to treat various types of cancer, including Hodgkin lymphoma, urothelial cancer, and breast cancer.
Research and Development[edit | edit source]
Seagen's research and development efforts are focused on creating a new generation of targeted, empowered therapies designed to help patients with cancer. The company's pipeline includes several investigational drugs at various stages of clinical testing.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
